Matrixyl research monograph — the Pal-KTTKS topical collagen peptide (cosmetic, not systemic)

Matrixyl is a cosmetic topical peptide — Palmitoyl Pentapeptide-4 (Pal-KTTKS), a matrikine (a collagen-fragment messenger peptide) trademarked by Sederma. It is not an injectable or systemic research peptide.

Class

Cosmetic topical peptide; Palmitoyl Pentapeptide-4 (Pal-KTTKS), a matrikine. Single compound.

Mechanism

The pentapeptide KTTKS, a fragment of procollagen, is conjugated to a palmitoyl fatty acid to improve skin penetration. As a matrikine it signals dermal fibroblasts to increase production of collagen, elastin, and other extracellular-matrix components — in effect a "sub-injury" repair signal applied topically.

Research summary

Important context: the evidence base is cosmetic and dermatological (topical), not systemic or injectable. Within that domain it is reasonably supported. In vitro, Pal-KTTKS at roughly 8 ppm raised collagen synthesis by about 90% in human dermal fibroblasts. Topical clinical trials — including double-blind, split-face randomized controlled trials reported in the International Journal of Cosmetic Science — show wrinkle-depth and skin-roughness reductions of roughly 15–37% over 4–12 weeks, with tolerability better than retinol. None of this transfers to injectable or systemic use; Matrixyl's evidence base should not be equated with that of injected research peptides.

Studied protocols

Topical leave-on formulations (serums and creams), typically applied once or twice daily over weeks. There is no studied injectable or systemic protocol.

Stacking research

Cosmetic formulations often combine it with other matrikines (for example "Matrixyl 3000," which pairs palmitoyl tripeptide-1 with palmitoyl tetrapeptide-7) and with retinol or vitamin C; combination data are formulation-level cosmetic claims.

Clinical / safety context

Used as a cosmetic ingredient with a strong topical tolerability record; it is not a drug and no systemic exposure is intended. Safety beyond topical use is uncharacterized.

Evidence quality — Moderate, but only for topical cosmetic use

There is reasonable topical cosmetic evidence and zero evidence for injection or systemic use.

Notes

Pal-KTTKS / palmitoyl pentapeptide-4 (historically labeled "-3"). This is a skincare ingredient; on a research-peptide platform it should be framed as topical-cosmetic, distinct from the injectable peptide catalogue.